Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
191
resultados
Última actualización
29/09/2025 [06:50:00]
Resumen de: CN120698908A
本申请提供了脂质化合物，例如式(I)的化合物。还提供了脂质纳米颗粒和药物组合物，其各自包含脂质化合物，例如下式的化合物。
Resumen de: CN120694966A
本发明涉及一种负载乏氧前药的上转换纳米颗粒的制备方法与应用。纳米颗粒由基于上转换纳米颗粒的纳米晶体与有机光敏剂复合，负载甘草酸和乏氧前药后组成。制备方法包含上转换纳米颗粒的制备，有机光敏剂的复合，甘草酸和乏氧前药的负载。本发明制备方法简单，能够有效负载光敏剂和乏氧前药，在808nm近红外光照射下具有高效的光动力治疗性能。甘草酸使纳米颗粒功能化靶向线粒体，光动力治疗引起的乏氧环境激活乏氧前药，引起肿瘤细胞的DNA损伤。进一步引起肿瘤免疫原性细胞死亡，增敏免疫检查点抑制剂的肿瘤免疫治疗疗效，为肿瘤免疫治疗提供新策略。
Resumen de: CN120694984A
本发明公开了一种自组装纳米颗粒及制备方法和应用、包含自组装纳米颗粒的外泌体包裹的纳米材料及应用，其中自组装纳米颗粒包括五味子酚和绿原酸，所述五味子酚和绿原酸混合形成纳米颗粒。本申请通过五味子酚和绿原酸自组装形成纳米颗粒，自组装纳米颗粒具备优异的抗氧化性能，自组装纳米颗粒被外泌体包裹形成纳米材料，纳米材料能够治疗肝损伤，促进特异性免疫耐受的形成。
Resumen de: CN120695172A
本发明提供一种以融合前构象GPC为靶标的拉沙病毒mRNA疫苗及其制备方法，涉及疫苗制备技术领域。所述拉沙病毒mRNA疫苗的氨基酸序列如SEQ ID NO.1所示，核酸序列如SEQ ID NO.2所示，且该疫苗为通过确定拉沙病毒的保守GPC氨基酸序列，并编码融合前构象GPC的氨基酸序列得到。本发明克服了现有技术的不足，能够设计并制备一款对LASV感染具有较好预防效果且安全稳定，研发周期短，成本低的疫苗。
Resumen de: WO2024148785A1
A method for evading a preexisting anti-PEG antibody in a human body, and the use of a PEGylated nano-carrier containing terminal hydroxyl in the preparation of a drug for evading a preexisting anti-PEG antibody in the human body. A PEGylated nano-carrier and nano-preparation containing terminal hydroxyl are included. The PEGylated nano-carrier and nano-preparation containing terminal hydroxyl have low binding with the preexisting anti-PEG antibody in the human body, and can thus evade being quickly cleared from the blood of the human body, so as to have a better treatment effect. In addition, by means of evading binding of the PEGylated nano-carrier and the nano-preparation containing terminal hydroxyl to the preexisting anti-PEG antibody in human blood, complement activation can be reduced, and side effects such as clinical injection reaction are reduced.
Resumen de: CN120694987A
本发明公开了牡荆素在制备弱精症药物中的应用，具体是以人类重链铁蛋白HFn纳米笼负载牡荆素VI形成HFn@VI纳米颗粒，用于制备弱精症药物。本发明统一了牡荆素的药理学和诊断潜力，为男性不育症的精准医学提供一个新的平台。
Resumen de: AU2024209122A1
Provided herein are composition including lipids and copolymers in the form of a nanodisc assembly. The copolymers include monomer units of methacrylic acid and styrene. Also provided herein is an aqueous solution comprising the subject composition, methods of producing the nanodisc assembly. Further provided are methods of solubilising hydrophobic constituents such as membrane proteins in aqueous solution, including forming nanodisc assemblies of a lipid, the hydrophobic constituent, and the subject copolymer.
Resumen de: AU2024210882A1
The present disclosure relates to RNA comprising one or more miRNA binding sequences, wherein the one or more miRNA binding sequences bind to miRNA that is present in cells in which expression of the RNA is not desired. Delivering the RNA to cells after administration, in particular after intramuscular or intravenous administration, allows expression of a polypeptide encoded by the RNA in certain cells while expression in other cells is repressed. In some embodiments, such cells comprise endothelial cells. RNA compositions described herein allow expression of a pharmaceutically active peptide or polypeptide by the RNA in a subject while reducing or avoiding the risks of undesired effects resulting from expression of the pharmaceutically active peptide or polypeptide in certain cells or tissues.
Resumen de: CN120695207A
本发明提出了一种ALKBH5在抑制结直肠癌PHF20表达中的用途，包括以下步骤：步骤一：选择合适ALKBH5过表达载体、并敲低PHF20、使用ALKBH5小分子激活剂或CRISPR、Cas9系统调控ALKBH5活性，从而显著抑制结直肠癌细胞的增殖和转移；步骤二：将调控元件递送至结直肠癌细胞或肿瘤组织，递送方式包括病毒载体、脂质体、局部注射或静脉注射，以提高治疗的精确性和有效性；步骤三：检测ALKBH5与PHF20表达水平的变化，评估肿瘤增殖、转移或耐药性的抑制效果。本发明核心在于证实ALKBH5抑制结直肠癌细胞中PHF20表达的作用，通过多种调控手段和递送系统，实现对结直肠癌细胞的增殖、转移和耐药性的抑制。此外，还提供了相应的药物组合物及诊断评估方法，为结直肠癌的治疗和预后提供了新的策略。
Resumen de: CN120694968A
本发明公开了一种脂质纳米粒、靶向脂质纳米粒及制备方法和应用。该脂质纳米粒具有核壳结构，内核为由含药物分子的PLGA纳米粒形成，外壳为由包括磷脂、胆固醇和修饰材料的原料形成；其中，含药物分子的PLGA纳米粒为由包括PLGA和药物分子的原料形成；PLGA与磷脂的质量比为1～5:1；磷脂与胆固醇的质量比为3～10:1，磷脂与修饰材料的质量比为3～10:1；药物分子选自难溶性药物、水溶性药物、基因和蛋白质中的一种或多种；所述修饰材料为PEG‑DSPE。本发明的脂质纳米粒的硬度可以调控，可以通过调控硬度以改善细胞摄取；本发明的靶向脂质纳米粒可以更好地改善细胞摄取，促进肠上皮细胞吸收，提高口服疗效。
Resumen de: CN120695198A
本申请设计了一种雨生红球藻外泌体包埋类胡萝卜素的制备方法，包括步骤S1、将雨生红球藻藻种接种于基础培养基进行育种培养并扩增；步骤S2、对基础培养基进行离心分离，并进行过滤浓缩获取雨生红球藻外泌体；步骤S3、将类胡萝卜素用二甲基亚砜或丙二醇溶解后，将雨生红球藻外泌体与类胡萝卜素混合，于32～40℃自然孵育1～4h，得到含有外泌体的类胡萝卜素。通过上述设计，本申请能够首次利用雨生红球藻外泌体作为载体包埋类胡萝卜素，显著提升脂溶性活性成分的稳定性和生物利用度，虾青素包封率达0.071％、岩藻黄素包封率达2.87％，且工艺全程可规模化操作，在医药、化妆品及功能食品领域具有广阔工业化应用前景。
Resumen de: MX2025009500A
The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.
Resumen de: CN120695167A
本发明公开了一种铈基靶向纳米药物及其应用和制备方法。本发明通过无载体配位驱动自组装技术，将水溶性葡萄糖氧化酶溶液和铈离子溶液与脂溶性替拉扎明溶液混合在一起，并通过官能团配位键获得无载体配位自驱动的铈基靶向纳米药物。本发明进一步通过反复冻融和差速离心方式高效制备了血小板膜，将其与铈基靶向纳米药物通过共挤出方式制备得到血小板膜仿生铈基靶向纳米药物，能够有效增强铈基靶向纳米药物的靶向性和生物安全性。本发明制备的药物稳定性好，具有优异的生物相容性、低毒性、高靶向性和高肿瘤杀伤性。
Resumen de: CN120694967A
本发明属于生物制药领域，具体涉及一种具有解毒功能的黄芩苷酵母微胶囊及其制备方法和应用。通过薄膜水化和酸碱‑有机制备出搭载黄芩苷的阳离子脂质体及酵母细胞壁，两者静电自沉积形成黄芩苷酵母微胶囊。实验表明本发明所述的黄芩苷酵母微胶囊可通过改善肾脏纤维化、机体炎症反应及促进毒素排出等途径改善了毒素对机体的损伤。本发明为黄芩苷的低生物利用度提供了一种纳米载体的改善策略，为黄芩苷改善赭曲霉毒素A造成的肾损伤提供科学依据。
Resumen de: CN120694969A
本发明涉及一种用于肾损伤的纳米硒制剂及其制备方法和应用，所述纳米硒制剂包括芯和壳，所述芯包括硒，所述壳包括二硬脂酰基磷脂酰乙醇胺‑聚乙二醇，所述壳包裹于所述芯的表面。制备方法包括如下步骤：包裹：将芯的原料、壳的原料分别溶于溶剂，得到芯材溶液、壳材溶液；将芯材溶液与壳材溶液混合，使壳的原料包裹于芯的原料的表面，得到含有纳米硒制剂前体的溶液；制备用于肾损伤的纳米硒制剂：将含有纳米硒制剂前体的溶液蒸干，加水重悬，得到用于肾损伤的纳米硒制剂。本发明的纳米硒制剂对AKI有较好的保护作用，具有良好的肾靶向性和生物安全性，能有效改善肾功能，减少肾组织病理学损伤，显著减轻线粒体损伤和细胞凋亡，具有剂量依赖性。
Resumen de: CN120694957A
本发明公开了一种抗肿瘤的透明质酸‑柚皮素自组装纳米颗粒的制备方法，属于医药领域。该方法通过透明质酸上的羧基与柚皮素上的羟基结合形成酯基，得到透明质酸‑柚皮素聚合物来进行。亲水性的透明质酸结合疏水性的柚皮素，形成亲疏水性聚合物，然后在水溶液中通过超声波的作用，疏水端排斥水分子而相互聚集，亲水端便包裹在疏水端外围，与水接触，从而形成内核是疏水性的柚皮素，外核是亲水性的透明质酸的纳米粒子。该纳米粒子的粒径为140~200nm，粒子稳定、均匀，体外释放实验结果说明能缓慢释放，细胞实验显示制剂能明显提高柚皮素对肿瘤细胞的毒性，说明其有良好的抗肿瘤活性。
Resumen de: CN120699882A
本发明公开了一种植物来源的挤压纳米囊泡的制备方法和应用，涉及生物医药技术领域。植物来源的挤压纳米囊泡的制备方法包括以下步骤：取洗净的植物根、茎、叶、花或果实榨汁得到植物汁液，用纱布过滤得到第一滤液；将第一滤液经过低速300‑6,000 ×g离心得第二滤液；将第二滤液于0‑5℃下依次经过8,000‑20,000 ×g离心0.5‑3 h，得到第一沉淀；将第一沉淀加至缓冲液中，超声，稀释，依次通过孔径0.4‑10 μm和孔径0.1‑0.4 μm的滤膜，得到第三滤液；将第三滤液离心，取沉淀重悬，得到挤压纳米囊泡。经实验检测，发现上述挤压囊泡特征与天然囊泡相似，但产量远远高于天然囊泡，可作为纳米载体应用于基础或临床。
Resumen de: WO2024054882A1
The present invention features method and composition that can be used to facilitate intracellular delivery of DNA to a subject. The provided methods and compositions employ a nanoparticle for intracellular DNA delivery and a type 1 interferon receptor pathway inhibitor. The type 1 interferon receptor pathway inhibitor is provided to decrease the subject's immune response that can be stimulated by the DNA.
Resumen de: CN119894918A
The present disclosure provides delivery vehicle compositions comprising a hydroxyalkyl terminated cationic peptoid, such as a 2-aminopropane-1, 3-diol terminated cationic peptoid, and complexes of the delivery vehicle with a polyanionic compound, such as a nucleic acid. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for delivering polyanionic compounds (e.g., nucleic acids) to cells. The present disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the present disclosure.
Resumen de: CN119768157A
The present invention relates to a kit for preparing nanoparticles containing a drug and a nanoparticle composition for delivering a drug, and more particularly, to a kit for preparing nanoparticles containing a drug and a nanoparticle composition for delivering a drug, the kit is designed to increase the cellular delivery efficiency of a drug by using nanoparticles comprising a cationic compound and an anionic polymer compound having at least one acidic functional group.
Resumen de: MX2025002804A
A sheet for radiotherapy, which includes a sheet base configured for placement on tissue of a patient and a radium-binding material coupled to the base sheet. Alpha-emitting radium radionuclides are coupled to the radium-binding material. The radium radionuclides do not leave the sheet, but radon and lead resulting from decay of the radium radionuclides easily leave the sheet.
Resumen de: WO2024054901A1
The present invention relates to novel piperazine compounds, in particular, of formula (I) or formula (II). These piperazine compounds can be used, for example, in lipid nanoparticle compositions for drug delivery and cancer treatments.
Resumen de: MX2025002927A
The present disclosure relates to a method for treating cancer in a subject that is BRCA-negative and homologous repair proficient (HRP), the method comprising administering to the subject a nucleic acid vector (e.g., a plasmid) comprising a polynucleotide that encodes an interleukin-12 (IL-12) formulated with a lipopolymer (e.g., a nanoparticle). In some aspects, the method further comprises administering to the subject an anticancer agent (e.g., a chemotherapeutic agent), an antibody or antigen-binding fragment thereof that specifically binds a vascular endothelial growth factor (VEGF) (anti-VEGF antibody), an immune checkpoint inhibitor, or any combination thereof.
Resumen de: JP2025024198A
To provide nucleic acid based compounds or polynucleotides having features which are useful for optimizing formulation and delivery of nucleic acid based therapeutics.SOLUTION: An isolated polynucleotide comprises: (a) a first region of linked nucleosides, the first region encoding a polypeptide of interest, the polypeptide of interest having prescribed sequences; (b) a first flanking region located at a 5' terminus of the first region, the first flanking region comprising (i) a sequence of linked nucleosides selected from a native 5' UTR and (ii) at least one 5' terminal cap; and (c) a second flanking region located at a 3' terminus of the first region, the second flanking region comprising (i') a sequence of linked nucleosides selected from a native 3' UTR and (ii') a 3' tailing sequence of linked nucleosides.SELECTED DRAWING: Figure 1
Nº publicación: WO2025198537A1 25/09/2025
Solicitante:
NANYANG TECHNOLOGICAL UNIV [SG]
NANYANG TECHNOLOGICAL UNIVERSITY
Resumen de: WO2025198537A1
The present invention provides methods for enhancing cellular binding or entry of a peptide coacervate composition utilising a peptide that comprises a cholesterol binding domain/motif. The invention also covers novel peptide coacervates that comprise a peptide that comprises a cholesterol binding domain/motif, optionally peptide coacervates that also comprises a payload, such as an active agent to be delivered into the cell, and their use in therapy or diagnosis.
BOPI
Sede Electrónica
